I will listen to the call again today, but I don't believe Rice was talking about Ven when he mentioned big pharma interest. I think any deal regarding TUSP would be for regional rights or co-marketing. I can't see them giving up the whole of TUSP. Rice is finally talking about combinations.
Guy's, I know Tusp shows "promise", but this company just keeps rolloing out the same story year after year with a different drug. I have very little confidence in LUX and they have to find a partner or buyer for the company. Hope of all hopes, someone buys this company for anything north of current market cap.
I don't know how many sites are open but I expect the rate of enrollment in the Aptivate trial to be high, especially as they open up sites that can do the Tusp/Ven combination. Expect oncologist to steer their patients towards the chance of getting into the Tusp/ven arm. This is a very big deal.
News 
Market Data 
Discover 
